癌症代谢重编程不仅是生物学上的一个特征，也揭示了治疗的弱点。许多代谢分子已经在临床前研究中显示出作为治疗靶点以阻断肿瘤进展的潜力，其中一些已经进入临床试验。然而，代谢网络的复杂性和适应性阻碍了代谢疗法的有效性。本综述总结了癌症治疗的代谢靶点，并提供了针对癌症代谢的临床试验的当前状态概述。此外，我们解读了限制代谢为基础的治疗疗效的关键因素，并提出了未来方向的建议。通过整合多组学、单细胞和空间技术的进步，以及更加精确和动态地跟踪代谢适应能力，临床医生可以为个性化代谢治疗以改善癌症治疗效果。版权 © 2023 Elsevier Inc. 保留所有权利。

Metabolic reprogramming in cancer is not only a biological hallmark but also reveals treatment vulnerabilities. Numerous metabolic molecules have shown promise as treatment targets to impede tumor progression in preclinical studies, with some advancing to clinical trials. However, the intricacy and adaptability of metabolic networks hinder the effectiveness of metabolic therapies. This review summarizes the metabolic targets for cancer treatment and provides an overview of the current status of clinical trials targeting cancer metabolism. Additionally, we decipher crucial factors that limit the efficacy of metabolism-based therapies and propose future directions. With advances in integrating multi-omics, single-cell, and spatial technologies, as well as the ability to track metabolic adaptation more precisely and dynamically, clinicians can personalize metabolic therapies for improved cancer treatment.Copyright © 2023 Elsevier Inc. All rights reserved.